Advertisement

Genetics of Oral Cancer

  • Anthony MorlandtEmail author
  • Hope Amm
Chapter

Abstract

In recent years, precision medicine and genomics have become key topics among surgeons and researchers seeking to understanding head and neck cancers. A delicate interaction between host immune response, oncogenic viruses and proteins, and regulatory genes drives the carcinogenesis. Mutagenic agents cause irreversible cell injury which leads to malignant transformation of preinvasive cell populations. For nearly a century, toxins such as cigarette smoke, alcohol, or chronic traumatic injury (e.g., Marjolin’s ulcer) have been implicated in the development of head and neck cancer. There is a modern shift from these classically held beliefs, however, toward understanding host genetic polymorphisms which may ultimately contribute to carcinogenesis to a greater degree than extrinsic injury. Eludicating the causal relationship between the genetics of oral cancer development and the treatment of the tumors themselves is critical to advancing the field of head and neck oncology and is a key focus of federal and foundation-based funding agencies.

Keywords

Malignant transformation Carcinogenesis Immunotherapy Precision medicine Tumor suppressor genes Oncoproteins Oncogenic virus mRNA Patient-derived xenografts 

References

  1. 1.
  2. 2.
    Tota JE, Anderson WF, Coffey C, Califano J, Cozen W, Ferris R, St. John M, Cohen E, Chaturvedi A. Rising incidence of oral tongue cancer among white men and women in the United States, 1973–2012. Oral Oncol. 2017;67:146–52.  https://doi.org/10.1016/j.oraloncology.2017.02.019.CrossRefPubMedGoogle Scholar
  3. 3.
    Farah CS, Jessri M, Currie S, Alnuaimi A, Yap T, McCullough M. Aetiology of oral cavity cancer. In: Kuriakose MA, editor. Contemporary oral oncology: biology, epidemiology, etiology, and prevention. New York, NY: Springer; 2017.CrossRefGoogle Scholar
  4. 4.
    Suresh A, Kuriakose M, Mohanta S, Siddapa G. Carcinogenesis and field cancerization in oral squamous cell carcinoma. In: Kuriakose MA, editor. Contemporary oral oncology: biology, epidemiology, etiology, and prevention. New York, NY: Springer; 2017.Google Scholar
  5. 5.
    Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576.  https://doi.org/10.1038/nature14129.CrossRefGoogle Scholar
  6. 6.
    Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol. 2008;44:1093–9.  https://doi.org/10.1016/j.oraloncology.2008.02.012.CrossRefPubMedGoogle Scholar
  7. 7.
    Sharma U, Singhal P, Bandil K, Kumar A, Bose S, Ahuja P, et al. Genetic variations of IL-10: Identification of novel variations and evaluation of the impact of the SNPs/haplotype in the promoter region with the progression of oral squamous cell carcinoma in indian population. Cytokine. 2018;103:99–108.  https://doi.org/10.1016/j.cyto.2017.09.016.CrossRefPubMedGoogle Scholar
  8. 8.
    Singh PK, Ahmad MK, Kumar V, Hussain SR, Gupta R, Jain A, et al. Effects of interleukin-18 promoter (C607A and G137C) gene polymorphisms and their association with oral squamous cell carcinoma (OSCC) in northern India. Tumour Biol. 2014;35:12275–84.  https://doi.org/10.1007/s13277-014-2538-0.CrossRefPubMedGoogle Scholar
  9. 9.
    Vairaktaris E, Yannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, et al. Strong association of interleukin-4 (−590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Europeans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:796–802.  https://doi.org/10.1016/j.tripleo.2006.12.029.CrossRefPubMedGoogle Scholar
  10. 10.
    Li N, Zhang C, Chen Z, Bai L, Nie M, Zhou B, et al. Interleukin 17A and interleukin 17F polymorphisms are associated with oral squamous cell carcinoma susceptibility in a Chinese population. J Oral Maxillofac Surg. 2015;73:267–73.  https://doi.org/10.1016/j.joms.2014.09.009.CrossRefPubMedGoogle Scholar
  11. 11.
    Chang JS, Lo HI, Wong TY, Huang CC, Lee WT, Tsai ST, Chen KC, Yen CJ, Wu YH, Hsueh WT, Yang MW, Wu SY, Chang KY, Chang JY, Ou CY, Wang YH, Weng YL, Yang HC, Wang FT, Lin CL, Huang JS, Hsiao JR. Investigating the association between oral hygiene and head and neck cancer. Oral Oncol. 2013;49:1010–7.  https://doi.org/10.1016/j.oraloncology.2013.07.004.CrossRefPubMedGoogle Scholar
  12. 12.
    Goda H, Okamoto M, Nakashiro KI, Hino S, Murase R, Hamakawa H. Prognostic impact of preoperative serum interleukin-6 levels in patients with early-stage oral squamous cell carcinoma, defined by sentinel node biopsy. Oncol Lett. 2017;14:7965–9.  https://doi.org/10.3892/ol.2017.7183.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Fang WY, Chen YW, Hsiao JR, Liu CS, Kuo YZ, Wang YC, et al. Elevated S100A9 expression in tumor stroma functions as an early recurrence marker for early-stage oral cancer patients through increased tumor cell invasion, angiogenesis, macrophage recruitment and interleukin-6 production. Oncotarget. 2015;6:28401–24.  https://doi.org/10.18632/oncotarget.4951.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Peng CY, Wang TY, Lee SS, Hsieh PL, Liao YW, Tsai LL, et al. Let-7c restores radiosensitivity and chemosensitivity and impairs stemness in oral cancer cells through inhibiting interleukin-8. J Oral Pathol Med. 2018;47:590–7.  https://doi.org/10.1111/jop.12711.CrossRefPubMedGoogle Scholar
  15. 15.
    Yang PW, Huang PM, Yong LS, Chang YH, Wu CW, Hua KT, et al. Circulating interleukin-6 is associated with prognosis and genetic polymorphisms of MIR608 in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2018;25:2449–56.  https://doi.org/10.1245/s10434-018-6532-4.CrossRefPubMedGoogle Scholar
  16. 16.
    Yap T, Koo K, Cheng L, Vella LJ, Hill AF, Reynolds E, et al. Predicting the presence of oral squamous cell carcinoma using commonly dysregulated microRNA in oral swirls. Cancer Prev Res (Phila). 2018;11:491–502.  https://doi.org/10.1158/1940-6207.CAPR-17-0409.CrossRefGoogle Scholar
  17. 17.
    Lien MY, Lin CW, Tsai HC, Chen YT, Tsai MH, Hua CH, et al. Impact of CCL4 gene polymorphisms and environmental factors on oral cancer development and clinical characteristics. Oncotarget. 2017;8:31424–34.  https://doi.org/10.18632/oncotarget.15615.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Heineman TE, Widman A, Kuan EC, St John M. The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer. Laryngosc Investig Otolaryngol. 2017;2:99–103.  https://doi.org/10.1002/lio2.79.CrossRefGoogle Scholar
  19. 19.
    Weber M, Wehrhan F, Baran C, Agaimy A, Buttner-Herold M, Preidl R, Neukam FW, Ries J. Pd-l1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. Oncotarget. 2017;8:112584–97.  https://doi.org/10.18632/oncotarget.22576.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52.  https://doi.org/10.1016/j.cell.2010.03.015.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lin SC, Chung MY, Huang JW, Shieh TM, Liu CJ, Chang KW. Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J Oral Pathol Med. 2004a;33:323–6.  https://doi.org/10.1111/j.1600-0714.2004.00214.x.CrossRefPubMedGoogle Scholar
  22. 22.
    Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW, Chang KW. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med. 2004b;33:405–9.  https://doi.org/10.1111/j.1600-0714.2004.00231.x.CrossRefPubMedGoogle Scholar
  23. 23.
    Nishizawa R, Nagata M, Noman AA, Kitamura N, Fujita H, Hoshina H, et al. The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer. 2007;7:187.  https://doi.org/10.1186/1471-2407-7-187.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chaudhary AK, Singh M, Bharti AC, Singh M, Shukla S, Singh AK, et al. Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (−1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer. 2010;10:369.  https://doi.org/10.1186/1471-2407-10-369.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Cao ZG, Li CZ. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances oral squamous cell carcinoma susceptibility in a Chinese population. Oral Oncol. 2006;42:32.  https://doi.org/10.1016/j.oraloncology.2004.08.015.CrossRefPubMedGoogle Scholar
  26. 26.
    Chaudhary AK, Pandya S, Mehrotra R, Singh M, Singh M. Role of functional polymorphism of matrix metalloproteinase-2 (−1306 C/T and −168 G/T) and MMP-9 (−1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers. 2011;16:577–86.  https://doi.org/10.3109/1354750X.2011.609602.CrossRefPubMedGoogle Scholar
  27. 27.
    O-Charoenrat P, Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol. 2006;42:257–67.  https://doi.org/10.1016/j.oraloncology.2005.07.008.CrossRefPubMedGoogle Scholar
  28. 28.
    Pereira AC, Dias do Carmo E, Dias da Silva MA, Blumer Rosa LE. Matrix metalloproteinase gene polymorphisms and oral cancer. J Clin Exp Dent. 2012;4:e297–301.  https://doi.org/10.4317/jced.50859.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lin CW, Yang SF, Chuang CY, Lin HP, Hsin CH. Association of matrix metalloproteinase-11 polymorphisms with susceptibility and clinicopathologic characteristics for oral squamous cell carcinoma. Head Neck. 2015;37:1425–31.  https://doi.org/10.1002/hed.23771.CrossRefPubMedGoogle Scholar
  30. 30.
    Thangaraj SV, Shyamsundar V, Krishnamurthy A, Ramani P, Ganesan K, Muthuswami M, et al. Molecular portrait of oral tongue squamous cell carcinoma shown by integrative meta-analysis of expression profiles with validations. PLoS One. 2016;11:e0156582.  https://doi.org/10.1371/journal.pone.0156582.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ramakodi MP, Devarajan K, Blackman E, Gibbs D, Luce D, Deloumeaux J, et al. Integrative genomic analysis identifies ancestry-related expression quantitative trait loci on DNA polymerase beta and supports the association of genetic ancestry with survival disparities in head and neck squamous cell carcinoma. Cancer. 2017;123:849–60.  https://doi.org/10.1002/cncr.30457.CrossRefPubMedGoogle Scholar
  32. 32.
    Murali A, Varghese BT, Kumar RR, Kannan S. Combination of genetic variants in cyclin D1 and retinoblastoma genes predict clinical outcome in oral cancer patients. Tumour Biol. 2016;37:3609–17.  https://doi.org/10.1007/s13277-015-4179-3.CrossRefPubMedGoogle Scholar
  33. 33.
    Liu KYP, Lu XJD, Zhu Y, Yip S, Poh CF. Altered immune-related gene expressions indicate oral cancer nodal disease. J Dent Res. 2018;97:709–16.  https://doi.org/10.1177/0022034518758045.CrossRefPubMedGoogle Scholar
  34. 34.
    Wang W, Lim WK, Leong HS, Chong FT, Lim TK, Tan DS, et al. An eleven gene molecular signature for extra-capsular spread in oral squamous cell carcinoma serves as a prognosticator of outcome in patients without nodal metastases. Oral Oncol. 2015;51:355–62.  https://doi.org/10.1016/j.oraloncology.2014.12.012.CrossRefPubMedGoogle Scholar
  35. 35.
    Multani S, Saranath D. Genotypic distribution of single nucleotide polymorphisms in oral cancer: global scene. Tumour Biol. 2016;37:14501–12.  https://doi.org/10.1007/s13277-016-5322-5.CrossRefPubMedGoogle Scholar
  36. 36.
    Yan Y, Wang X, Veno MT, Bakholdt V, Sorensen JA, Krogdahl A, Sun Z, Gao S, Kjems J. Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients. Oncotarget. 2017;8:8206.  https://doi.org/10.18632/oncotarget.14143.CrossRefPubMedGoogle Scholar
  37. 37.
    Pedersen NJ, Jensen DH, Lelkaitis G, Kiss K, Charabi BW, Ullum H, Specht L, Schmidt AY, Nielsen FC, von Buchwald C. MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma. Oral Oncol. 2018;83:46.  https://doi.org/10.1016/j.oraloncology.2018.05.020.CrossRefPubMedGoogle Scholar
  38. 38.
    Tipirneni KE, Rosenthal EL, Moore LS, Haskins AD, Udayakumar N, Jani AH, Carroll WR, Morlandt AB, Bogyo M, Rao J, Warram J. Fluorescence imaging for cancer screening and surveillance. Mol Imaging Biol. 2017;19:645–55.. https://do.org/10.1007/s11307-017-1050-5 CrossRefGoogle Scholar
  39. 39.
    Moore LS, Rosenthal EL, Chung TK, de Boer E, Patel N, Prince AC, Korb ML, Walsh EM, Young ES, Stevens TM, Withrow KP, Morlandt AB, Richman JS, Carroll WR, Zinn KR, Warram JM. Characterizing the utility and limitations of repurposing an open-field optical imaging device for fluorescence-guided surgery in head and neck cancer patients. J Nucl Med. 2017;58(2):246–51.  https://doi.org/10.2967/jnumed.115.171413.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Macey R, Walsh T, Brocklehurst P, Kerr AR, Liu JLY, Lingen M, Ogden G, Warnakulasuriya S, Scully C. Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions. Cochrane Database Syst Rev. 2015;5:CD010276.  https://doi.org/10.1002/14651858.CD010276.pub2.CrossRefGoogle Scholar
  41. 41.
    Sweeny L, Dean NR, Agnuson JS, Carroll WR, Clemons L, Rosenthal EL. Assessment of tissue autofluorescence and reflectance for oral cavity cancer screening. Otolaryngol Head Neck Surg. 2011;145(6):956–60.  https://doi.org/10.1177/0194599811416773.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Polverini PJ, D’Silva NJ, Lei YL. Precision therapy of head and neck squamous cell carcinoma. J Dent Res. 2018;97:614–21.  https://doi.org/10.1177/0022034518769645.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Chia S, Low JL, Zhang X, Kwang XL, Chong FT, Sharma A, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017;8:435.  https://doi.org/10.1038/s41467-017-00451-5.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Slosberg ED, Kang BP, Peguero J, Taylor M, Bauer TM, Berry DA, Braiteh F, Spira A, Meric-Bernstam F, Stein S, Piha-Paul SA, Salvado A. Signature program: a platform of basket trials. Oncotarget. 2018;9:21383.  https://doi.org/10.18632/oncotarget.25109.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Section of Oral Oncology, Department of Oral and Maxillofacial SurgeryUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Department of Oral and Maxillofacial SurgeryUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations